<DOC>
	<DOC>NCT00986349</DOC>
	<brief_summary>The main objective of the study is to demonstrate the safety and efficacy of the Gastrointestinal (GI) EndoBarrier in the glycemic control of diabetes in subjects with Type 2 diabetes.</brief_summary>
	<brief_title>Study of EndoBarrier Liner for Treatment of Type 2 Diabetes Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Subjects Age &gt; 18 years and ≤ 55 years Male or Female Subjects with Type 2 Diabetes who have been treated for ≤10 years and are on oral diabetic medications Subjects with an HbA1C &gt; 7.5 and ≤ 10.0% Subjects with a BMI &gt; 26 &lt; 50 Subjects willing to comply with study requirements Subjects who have signed an informed consent form Women who are postmenopausal, surgically sterile or on oral contraceptives and agree to remain on oral contraceptives for at least twentyfour (24) weeks after being implanted or the duration of their trial participation and agree not to become pregnant during the trial. Subjects diagnosed with Type 1 Diabetes Mellitus or having a history of ketoacidosis Subjects requiring insulin Subjects with probable insulin production failure (fasting C Peptide serum &lt;1ng/mL) Subjects that have autoimmune disease as evidenced by a positive antiGAD blood test Subjects with a weight loss of &gt; 4.5 Kg (10 lbs) within the 12 Weeks of screening Subjects requiring prescription anticoagulation therapy Subjects with or a history of iron deficiency and/or iron deficiency anemia Subjects with or a history of abnormalities of the GI tract Subjects with symptomatic gallstones or kidney stones at the time of screening Subjects with a known infection Subjects with or a history of coagulopathy, upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia Subjects mentally retarded or emotionally unstable, or exhibits psychological characteristics which, in the opinion of the Investigator, makes the Subject a poor candidate for device placement or clinical trial participation Subjects with previous GI surgery that could affect the ability to place the device or the function of the implant Subjects unable to discontinue NSAIDs (nonsteroidal antiinflammatory drugs) during the implant period Subjects with active H. pylori (Note: Subjects may be enrolled if they had a prior history of H. Pylori and were successfully treated) Subjects receiving weight loss medications such as Meridia, Xenical, or over the counter weight loss medications Subject or Family history of a known diagnosis or preexisting symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder Subjects with active and uncontrolled GERD Subjects with a known history of substance abuse Subjects participating in another ongoing investigational clinical trial Subjects taking corticosteroids or drugs known to affect GI motility (i.e. Reglan)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>GI Dynamics</keyword>
	<keyword>EndoBarrier</keyword>
</DOC>